SOURCE: Market Pulse

July 01, 2005 08:30 ET

Market Pulse Breaking News Alert for Friday, July 1, 2005: BIPH -- Biophan Executes Definitive Agreements With Boston Scientific!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- July 1, 2005 -- Market Pulse News Alert for this AM, Stocks to Watch are: Biophan Technologies, Inc. (OTC BB: BIPH), Google Inc. (NASDAQ: GOOG), Volcom Inc. (NASDAQ: VLCM), and MBNA Corp. (NYSE: KRB).

Investors need to be watching Biophan Technologies, Inc. (OTC BB: BIPH) this AM! Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. Biophan's technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Biophan has joint development arrangements with Boston Scientific and NASA's Ames Center for Nanotechnology. BIPH has had several excellent news announcements lately and one again after Thursday's bell announcing it has reached a definitive agreement with Boston Scientific Corporation on an equity investment and technology license! This could be great news for investors!

Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation medical technology, today announced it has reached a definitive agreement with Boston Scientific Corporation on an equity investment and technology license. The equity transaction consists of the purchase of Biophan common stock totaling $5 million, priced at a 10% premium over the average of the closing price for the 30 calendar-day period prior to the closing. The technology license includes an upfront payment of $750,000 and annual maintenance fees, in addition to royalties and milestone payments. The balance of the financial details were not disclosed. Funding under both agreements is expected to occur following confirmation of paperwork related to our recent acquisitions.

The license agreement covers multiple patents related to Magnetic Resonance Imaging (MRI) safety and image compatibility, and includes both exclusive and non-exclusive product categories. Biophan is a leader in the development of nanotechnology and other technology solutions that make surgical tools and implantable medical devices safe and image-compatible for use in MRI systems.

"We are very pleased to be providing Boston Scientific with access to our technology solutions," said Michael Weiner, CEO of Biophan. "They are a bold innovator in the medical device sector and were the first major device company to take a serious interest in our technology solutions. Biophan's proprietary technology solutions may have applications across several Boston Scientific product lines."

Biophan had signed a multi-phase term sheet for a joint development agreement with Boston Scientific in November of 2003, covering Biophan's unique MRI-safe and MRI-image compatible technology.

"In the two years during which we have been working with Boston Scientific, we have expanded the size of our overall IP portfolio nearly threefold, from 54 to 140 U.S. issued and pending patents, and nearly 46 international patents and applications," said Mr. Weiner. "We have also expanded our technology base internally and via acquisitions."

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 140 U.S. patents, licenses, or applications. This total includes 38 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 93 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Stocks in the news and acting well as of late include: Google Inc. (NASDAQ: GOOG), Volcom Inc. (NASDAQ: VLCM), and MBNA Corp. (NYSE: KRB).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated two hundred thousand dollars from Biophan Technologies, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information